Christopher Von Seggern stepped down as Chief Commercial Officer of Xenon Pharmaceuticals Inc. and departed from the company. In connection with his departure ...

Assenagon Asset Management S.A. raised its position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Free Report) by 12.4% during the 4th quarter, HoldingsChannel reports. The fund owned 238,522 shares of ...

Topline data from the first Phase 3 FOS study anticipated in H2 2025 representing major milestone in support of NDA filing and potential launch ...

For the mountaineers, climbing the peaks of Mount Everest is the piece de resistance of their careers. What a lot of people don't realize is that accomplishing ...

About Xenon Pharmaceuticals Inc. Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing ...

Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a $3 billion market cap pharmaceutical company specializing in the development of therapeutic drugs, announced today the departure of its Chief Commercial ...

Xenon has promising Phase 2 data for MDD treatment, robust financials, and a potential in niche markets, despite premium ...

About Xenon Pharmaceuticals Inc. Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing ...

Recently, the Financial Times released an article featuring a climbing company whose goal is to offer their clients the use of xenon gas to make acclimatizing safer and to cut down the length of ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

International Isotopes Inc. (OTCQB: INIS) ("International Isotopes," "INIS" or the "Company") is pleased to announce that it ...